Educational content on VJHemOnc is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.

Share this video  

ASH 2021 | Factors affecting the efficacy of COVID-19 vaccination in patients with AL amyloidosis

In this video, Efstathios Kastritis, MD, University of Athens School of Medicine, Athens, Greece, discusses some findings from a large prospective study which investigated the efficacy of COVID-19 vaccination in patients with light chain (AL) amyloidosis. Dr Kastritis explains the factors which affected antibody response in patients following vaccination, including the use of various therapies, such as daratumumab and bortezomib. This interview took place at the 63rd ASH Annual Meeting and Exposition congress, Atlanta, GA, 2021.